تجویز داخلصفاقی میرتنول باعث کاهش آسیب ایسکمی ریه-پرفیوژن مجدد در موش بزرگ آزمایشگاهی میشود.

Introduction: Ischemia-reperfusion injury (IRI) is associated with the generation of reactive oxygen species, endothelial cell damage, increased vascular permeability, and the activation of neutrophils and cytokines. Myrtenol, a monoterpene alcohol, has been extensively studied and demonstrated to possess anti-inflammatory, antioxidant, and anti-apoptotic properties, offering protective effects against myocardial ischemia reperfusion injury. In this study, we aimed to investigate the effects of intraperitoneal injection of myrtenol on lung ischemia reperfusion injury. Methods and Materials: Wistar rats were categorized into four distinct groups for the study. These groups consisted of a sham group, a lung ischemia-reperfusion group, a vehicle+LIR group, and a myrtenol+LIR group. In the lung ischemia-reperfusion group, the rats were subjected to 60 minutes of ischemia followed by 120 minutes of reperfusion. The vehicle+LIR group received DMSO at a concentration of 0.5%. The myrtenol+LIR group received daily intraperitoneal injections of myrtenol for one week prior to lung ischemia-reperfusion. Various oxidative stress markers, namely SOD, superoxide dismutase, GPx, glutathione peroxidase, MDA, malondialdehyde, TOS, total oxidant status, and TAC, total antioxidant capacity, were evaluated, along with inflammatory factors Tumor necrosis factor alpha and Interleukin-6 (TNF-α and IL-6). Results: In the ischemia-reperfusion group, our results revealed a notable elevation in MDA, TOS, IL-6, and TNFα levels compared to the sham group, indicating increased oxidative stress and pro-inflammatory activity. Moreover, the activity of SOD, GPx and IL-10 was reduced in the ischemia-reperfusion group. However, when myrtenol was administered as a pretreatment, there was a significant reduction in the levels of pro-inflammatory cytokines and oxidative stress markers. Furthermore, myrtenol supplementation was found to enhance the production of antiinflammatory cytokines and antioxidant agents. Conclusion: Our findings highlight the remarkable protective effect of intraperitoneal injection of myrtenol against lung Ischemia reperfusion. [ABSTRACT FROM AUTHOR]